Advanced Nanotherapies Announces Closing Of Oversubscribed $7.2 Million Series A Financing
06/28/22, 8:03 AM
Location
los gatosMoney raised
$7.2 million
Round Type
series a
Advanced NanoTherapies, Inc., a privately-held medical device company committed to solving vascular disease's most significant challenges through the creative applications of nanotechnology, today announced the closing of its oversubscribed $7.2 million Series A equity financing, marking a total of $12.5 million raised since September 2020. Funds will be used to complete the first-in-human clinical study in Australia of the SirPlux Duo drug-coated balloon (DCB) in de-novo coronary artery disease (CAD) lesions. Funding comes from various sources in the U.S., Canada, Europe, and Asia.
Company Info
Location
los gatos, california, united states
Additional Info
The Advanced NanoTherapies nanoparticle drug-encapsulation and delivery platform provides safe, reliable, and sustained bioavailability of the two synergistic drugs in tissue. The company focuses on minimally invasive cardiovascular applications to bring a safer therapeutic option to patients with coronary artery disease (CAD) or peripheral artery disease (PAD). About Advanced NanoTherapiesAdvanced NanoTherapies, Inc. is a highly specialized medical device company developing a nanoparticle technology-based platform for drug delivery.